Hg. Demers et M. Schlander, DOSE TITRATION OF LOW-MOLECULAR-WEIGHT HEPARIN IN PATIENTS UNDERGOINGCHRONIC-HEMODIALYSIS, Nieren- und Hochdruckkrankheiten, 22(4), 1993, pp. 172-176
Low molecular weight (1 mw) heparins may be used in haemodialysis to p
revent clotting in the extracorporal circulation. In a clinical pilot
trial, eight patients undergoing chronic haemodialysis were treated fo
r six months with a 1 mw heparin. For each patient the dosage was titr
ated as to avoid thrombosis in the dialysis system. The doses required
ranged interindividually between 1,083 and 4,500 aPTT units (mean: 2,
780 units) but were intraindividually constant throughout the study pe
riod. Clinical efficacy was associated with antifactor Xa activities o
f 0.4 +/- 0.1 U/ml during dialysis. Compared with the last six months
prior to study entry, the patients needed 12 percent less erythrocyte
concentrates. No side effects of the 1 mw heparin were observed.